Literature DB >> 17662610

Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse.

Sylvia E Perez1, Saleem Dar, Milos D Ikonomovic, Steven T DeKosky, Elliott J Mufson.   

Abstract

The impact of Abeta deposition upon cholinergic intrinsic cortical and striatal, as well as basal forebrain long projection neuronal systems was qualitatively and quantitatively evaluated in young (2-6 months) and middle-aged (10-16 months) APPswe/PS1DeltaE9 transgenic (tg) mice. Cholinergic neuritic swellings occurred as early as 2-3 months of age in the cortex and hippocampus and 5-6 months in the striatum of tg mice. However, cholinergic neuron number or choline acetyltransferase (ChAT) optical density measurements remained unchanged in the forebrain structures with age in APPswe/PS1DeltaE9 tg mice. ChAT enzyme activity decreased significantly in the cortex and hippocampus of middle-aged tg mice. These results suggest that Abeta deposition has age-dependent effects on cortical and hippocampal ChAT fiber networks and enzyme activity, but does not impact the survival of cholinergic intrinsic or long projection forebrain neurons in APPswe/PS1DeltaE9 tg mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17662610      PMCID: PMC2245889          DOI: 10.1016/j.nbd.2007.06.015

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  97 in total

1.  Cholinergic systems in mammalian brain identified with antibodies against choline acetyltransferase.

Authors:  B H Wainer; A I Levey; E J Mufson; M M Mesulam
Journal:  Neurochem Int       Date:  1984       Impact factor: 3.921

2.  Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth.

Authors:  E H Koo; L Park; D J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

3.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

4.  Alzheimer's disease: striatal amyloid deposits and neurofibrillary changes.

Authors:  H Braak; E Braak
Journal:  J Neuropathol Exp Neurol       Date:  1990-05       Impact factor: 3.685

5.  Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes.

Authors:  D Hernandez; K Sugaya; T Qu; E McGowan; K Duff; M McKinney
Journal:  Neuroreport       Date:  2001-05-25       Impact factor: 1.837

6.  Correlative decrease of large neurons in the neostriatum and basal nucleus of Meynert in Alzheimer's disease.

Authors:  K Oyanagi; H Takahashi; K Wakabayashi; F Ikuta
Journal:  Brain Res       Date:  1989-12-18       Impact factor: 3.252

7.  Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

Authors:  Steven T DeKosky; Milos D Ikonomovic; Scot D Styren; Laurel Beckett; Stephen Wisniewski; David A Bennett; Elizabeth J Cochran; Jeffrey H Kordower; Elliott J Mufson
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

8.  Degeneration of beta-amyloid-associated cholinergic structures in transgenic APP SW mice.

Authors:  Hans-Joachim Lüth; Jenny Apelt; Amadi O Ihunwo; Thomas Arendt; Reinhard Schliebs
Journal:  Brain Res       Date:  2003-07-04       Impact factor: 3.252

9.  Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations.

Authors:  Julianne A Lombardo; Edward A Stern; Megan E McLellan; Stephen T Kajdasz; Gregory A Hickey; Brian J Bacskai; Bradley T Hyman
Journal:  J Neurosci       Date:  2003-11-26       Impact factor: 6.167

10.  The impact of Abeta-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in alzheimer's disease-like transgenic mice.

Authors:  L Hu; T P Wong; S L Côté; K F S Bell; A C Cuello
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

View more
  44 in total

1.  The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease.

Authors:  Mari Paz Serrano; Raquel Herrero-Labrador; Hunter S Futch; Julia Serrano; Alejandro Romero; Ana Patricia Fernandez; Abdelouahid Samadi; Mercedes Unzeta; Jose Marco-Contelles; Ricardo Martínez-Murillo
Journal:  J Psychiatry Neurosci       Date:  2017-01       Impact factor: 6.186

2.  Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development.

Authors:  Xue-Mei Zhang; Yan Cai; Kun Xiong; Huaibin Cai; Xue-Gang Luo; Jia-Chun Feng; Richard W Clough; Robert G Struble; Peter R Patrylo; Xiao-Xin Yan
Journal:  Eur J Neurosci       Date:  2009-12-10       Impact factor: 3.386

3.  Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease.

Authors:  Sylvia E Perez; Stephen Lumayag; Beatrix Kovacs; Elliott J Mufson; Shunbin Xu
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-09-12       Impact factor: 4.799

4.  Basal forebrain cholinergic modulation of sleep transitions.

Authors:  Simal Ozen Irmak; Luis de Lecea
Journal:  Sleep       Date:  2014-12-01       Impact factor: 5.849

5.  Immunohistochemical Analysis of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) Expression in the Rat and Human Hippocampus: Decline in CA3 During Progression of Alzheimer's Disease.

Authors:  Stephanie L Adams; Laurent Benayoun; Kathy Tilton; Tiffany J Mellott; Sudha Seshadri; Jan Krzysztof Blusztajn; Ivana Delalle
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

6.  BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer's disease.

Authors:  Rebecca M Burke; Timothy A Norman; Tarik F Haydar; Barbara E Slack; Susan E Leeman; Jan Krzysztof Blusztajn; Tiffany J Mellott
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

7.  Amyloid-beta expression in retrosplenial cortex of triple transgenic mice: relationship to cholinergic axonal afferents from medial septum.

Authors:  R T Robertson; J Baratta; J Yu; F M LaFerla
Journal:  Neuroscience       Date:  2009-09-20       Impact factor: 3.590

8.  Phospho-eIF2α level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice.

Authors:  Latha Devi; Masuo Ohno
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

9.  Rapid β-amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice.

Authors:  Juan Jose Ramos-Rodriguez; Mar Pacheco-Herrero; Diana Thyssen; Maria Isabel Murillo-Carretero; Esther Berrocoso; Tara L Spires-Jones; Brian J Bacskai; Monica Garcia-Alloza
Journal:  J Neuropathol Exp Neurol       Date:  2013-04       Impact factor: 3.685

10.  Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: relevance to Alzheimer's disease.

Authors:  Karim Belarbi; Katharina Schindowski; Sylvie Burnouf; Raphaëlle Caillierez; Marie-Eve Grosjean; Dominique Demeyer; Malika Hamdane; Nicolas Sergeant; David Blum; Luc Buée
Journal:  Curr Alzheimer Res       Date:  2009-04       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.